Syndax Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $16.81
- Today's High:
- $17.37
- Open Price:
- $17.31
- 52W Low:
- $16.81
- 52W High:
- $29.86
- Prev. Close:
- $17.36
- Volume:
- 1376942
Company Statistics
- Market Cap.:
- $1.21 billion
- Book Value:
- 5.762
- Revenue TTM:
- $126.58 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $139.71 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.79%
- Return on Equity TTM:
- -42.08%
Company Profile
Syndax Pharmaceuticals Inc had its IPO on 2016-03-03 under the ticker symbol SNDX.
The company operates in the Healthcare sector and Biotechnology industry. Syndax Pharmaceuticals Inc has a staff strength of 107 employees.
Stock update
Shares of Syndax Pharmaceuticals Inc opened at $17.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.81 - $17.37, and closed at $17.29.
This is a -0.4% slip from the previous day's closing price.
A total volume of 1,376,942 shares were traded at the close of the day’s session.
In the last one week, shares of Syndax Pharmaceuticals Inc have slipped by -11.56%.
Syndax Pharmaceuticals Inc's Key Ratios
Syndax Pharmaceuticals Inc has a market cap of $1.21 billion, indicating a price to book ratio of 4.8719 and a price to sales ratio of 12.6667.
In the last 12-months Syndax Pharmaceuticals Inc’s revenue was $126.58 million with a gross profit of $139.71 million and an EBITDA of $-172851008. The EBITDA ratio measures Syndax Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Syndax Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -25.79% with a return of equity of -42.08%.
In Q2, Syndax Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 33297.4%.
Syndax Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Syndax Pharmaceuticals Inc’s profitability.
Syndax Pharmaceuticals Inc stock is trading at a EV to sales ratio of 10.2528 and a EV to EBITDA ratio of -119.9522. Its price to sales ratio in the trailing 12-months stood at 12.6667.
Syndax Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $431.34 million
- Total Liabilities
- $30.17 million
- Operating Cash Flow
- $73.91 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Syndax Pharmaceuticals Inc ended 2024 with $431.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $431.34 million while shareholder equity stood at $400.04 million.
Syndax Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $30.17 million in other current liabilities, 7000.00 in common stock, $-778781000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $97.28 million and cash and short-term investments were $406.02 million. The company’s total short-term debt was $968,000 while long-term debt stood at $0.
Syndax Pharmaceuticals Inc’s total current assets stands at $409.08 million while long-term investments were $19.48 million and short-term investments were $308.75 million. Its net receivables were $534000.00 compared to accounts payable of $10.98 million and inventory worth $2.24 million.
In 2024, Syndax Pharmaceuticals Inc's operating cash flow was $73.91 million while its capital expenditure stood at $0.
Comparatively, Syndax Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $17.29
- 52-Week High
- $29.86
- 52-Week Low
- $16.81
- Analyst Target Price
- $36.33
Syndax Pharmaceuticals Inc stock is currently trading at $17.29 per share. It touched a 52-week high of $29.86 and a 52-week low of $29.86. Analysts tracking the stock have a 12-month average target price of $36.33.
Its 50-day moving average was $19.62 and 200-day moving average was $22.14 The short ratio stood at 9.05 indicating a short percent outstanding of 0%.
Around 416.6% of the company’s stock are held by insiders while 10718% are held by institutions.
Frequently Asked Questions About Syndax Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.